UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Kinase Fusion Gene:STK10_SNX2 |
Kinase Fusion Protein Summary |
Kinase Fusion gene summary |
Kinase Fusion partner gene information | Kinase Fusion gene name: STK10_SNX2 | KinaseFusionDB ID: KFG6123 | FusionGDB2.0 ID: KFG6123 | Hgene | Tgene | Gene symbol | STK10 | SNX2 | Gene ID | 6793 | 6643 | |
Gene name | serine/threonine kinase 10 | sorting nexin 2 | ||||||||||
Synonyms | LOK|PRO2729 | TRG-9 | ||||||||||
Cytomap | 5q35.1 | 5q23.2 | ||||||||||
Type of gene | protein-coding | protein-coding | ||||||||||
Description | serine/threonine-protein kinase 10lymphocyte-oriented kinase | sorting nexin-2CTB-36H16.2transformation-related gene 9 protein | ||||||||||
Modification date | 20240305 | 20240305 | ||||||||||
UniProtAcc | O94804 | Q9Y343 | ||||||||||
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000176763, ENST00000517775, | ENST00000510372, ENST00000379516, ENST00000514949, | |||||||||
Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: STK10 [Title/Abstract] AND SNX2 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | STK10(171614891)-SNX2(122161745), # samples:3 |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | STK10 | GO:0046777 | protein autophosphorylation | 12639966|18239682 |
Tgene | SNX2 | GO:0072673 | lamellipodium morphogenesis | 20604901 |
Kinase Fusion gene breakpoints across STK10 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Kinase Fusion gene breakpoints across SNX2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
Kinase Fusion gene information. |
Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
ChimerDB4 | TCGA-AB-2875-03A | STK10 | chr5 | 171509329 | SNX2 | chr5 | 122153043 |
ChimerDB4 | TCGA-BH-A0HL-01A | STK10 | chr5 | 171614891 | SNX2 | chr5 | 122161745 |
ChimerDB4 | TCGA-BH-A0HL | STK10 | chr5 | 171614890 | SNX2 | chr5 | 122161744 |
Top |
Kinase Fusion ORF Analysis |
Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
ENST00000176763 | ENST00000379516 | STK10 | chr5 | 171509329 | SNX2 | chr5 | 122153043 | 3372 | 961 |
Top |
Kinase Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq >ENST00000176763_ENST00000379516_STK10_chr5_171509329_SNX2_chr5_122153043_length(amino acids)=961 MERVRGSRRQGWAGQELRGRHKGGGPGDLTGRGRGRARRRLRGSGCSRRGAAQGTLDRGRAAGKGGSGENPERRGVLQLLLLLLAAAEAT ARARARARAGATAPPAMAFANFRRILRLSTFEKRKSREYEHVRRDLDPNEVWEIVGELGDGAFGKVYKAKNKETGALAAAKVIETKSEEE LEDYIVEIEILATCDHPYIVKLLGAYYHDGKLWIMIEFCPGGAVDAIMLELDRGLTEPQIQVVCRQMLEALNFLHSKRIIHRDLKAGNVL MTLEGDIRLADFGVSAKNLKTLQKRDSFIGTPYWMAPEVVMCETMKDTPYDYKADIWSLGITLIEMAQIEPPHHELNPMRVLLKIAKSDP PTLLTPSKWSVEFRDFLKIALDKNPETRPSAAQLLEHPFVSSITSNKALRELVAEAKAEVMEEIEDGRDEGEEEDAVDAASTLENHTQNS SEVSPPSLNADKPLEESPSTPLAPSQSQDSVNEPCSQPSGDRSLQTTSPPVVAPGNENGLAVPVPLRKSRPVSMDARIQVAQEKQVAEQG GDLSPAANRSQKASQSRPNSSALETLGGEKLANGSLEPPAQAAPGPSKRDSDCSSLCTSESMDYGTNLSTDLSLNKEMGSLSIKDPKLYK KTLKRTRKFVVDGVEVSITTSKIISEDEKKDEEMRFLRRQELRELRLLQKEEHRNQTQLSNKHELQLEQMHKRFEQEINAKKKFFDTELE NLERQQKQQVEKMEQDHAVRRREEARRIRLEQDRDYTRFQEQLKLMKKEEALVCHRKELSANTAAFAKSAAMLGNSEDHTALSRALSQLA EVEEKIDQLHQEQAFADFYMFSELLSDYIRLIAAVKGVFDHRMKCWQKWEDAQITLLKKREAEAKMMVANKPDKIQQAKNEIREWEAKVQ -------------------------------------------------------------- |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:171614891/chr5:122161745) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
STK10 | SNX2 |
FUNCTION: Serine/threonine-protein kinase involved in regulation of lymphocyte migration. Phosphorylates MSN, and possibly PLK1. Involved in regulation of lymphocyte migration by mediating phosphorylation of ERM proteins such as MSN. Acts as a negative regulator of MAP3K1/MEKK1. May also act as a cell cycle regulator by acting as a polo kinase kinase: mediates phosphorylation of PLK1 in vitro; however such data require additional evidences in vivo. {ECO:0000269|PubMed:11903060, ECO:0000269|PubMed:12639966, ECO:0000269|PubMed:19255442}. | FUNCTION: May be involved in several stages of intracellular trafficking. {ECO:0000250}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Hgene | STK10 | 171509329 | SNX2 | 122153043 | ENST00000176763 | 12 | 19 | 36_294 | 6631 | 969 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase Fusion Protein Structures |
CIF files of the predicted kinase fusion proteins * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
Kinase Fusion protein CIF link (fusion AA seq ID in KinaseFusionDB) | Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | AA seq | Len(AA seq) |
PDB file >>>257_STK10_SNX2 | ENST00000176763 | ENST00000379516 | STK10 | chr5 | 171509329 | SNX2 | chr5 | 122153043 | MERVRGSRRQGWAGQELRGRHKGGGPGDLTGRGRGRARRRLRGSGCSRRGAAQGTLDRGRAAGKGGSGENPERRGVLQLLLLLLAAAEAT ARARARARAGATAPPAMAFANFRRILRLSTFEKRKSREYEHVRRDLDPNEVWEIVGELGDGAFGKVYKAKNKETGALAAAKVIETKSEEE LEDYIVEIEILATCDHPYIVKLLGAYYHDGKLWIMIEFCPGGAVDAIMLELDRGLTEPQIQVVCRQMLEALNFLHSKRIIHRDLKAGNVL MTLEGDIRLADFGVSAKNLKTLQKRDSFIGTPYWMAPEVVMCETMKDTPYDYKADIWSLGITLIEMAQIEPPHHELNPMRVLLKIAKSDP PTLLTPSKWSVEFRDFLKIALDKNPETRPSAAQLLEHPFVSSITSNKALRELVAEAKAEVMEEIEDGRDEGEEEDAVDAASTLENHTQNS SEVSPPSLNADKPLEESPSTPLAPSQSQDSVNEPCSQPSGDRSLQTTSPPVVAPGNENGLAVPVPLRKSRPVSMDARIQVAQEKQVAEQG GDLSPAANRSQKASQSRPNSSALETLGGEKLANGSLEPPAQAAPGPSKRDSDCSSLCTSESMDYGTNLSTDLSLNKEMGSLSIKDPKLYK KTLKRTRKFVVDGVEVSITTSKIISEDEKKDEEMRFLRRQELRELRLLQKEEHRNQTQLSNKHELQLEQMHKRFEQEINAKKKFFDTELE NLERQQKQQVEKMEQDHAVRRREEARRIRLEQDRDYTRFQEQLKLMKKEEALVCHRKELSANTAAFAKSAAMLGNSEDHTALSRALSQLA EVEEKIDQLHQEQAFADFYMFSELLSDYIRLIAAVKGVFDHRMKCWQKWEDAQITLLKKREAEAKMMVANKPDKIQQAKNEIREWEAKVQ | 961 |
3D view using mol* of 257_STK10_SNX2 | ||||||||||
PDB file >>>HKFP_377_STK10_SNX2 | ENST00000176763 | ENST00000379516 | STK10 | chr5 | 171509329 | SNX2 | chr5 | 122153043 | MERVRGSRRQGWAGQELRGRHKGGGPGDLTGRGRGRARRRLRGSGCSRRGAAQGTLDRGRAAGKGGSGENPERRGVLQLLLLLLAAAEAT ARARARARAGATAPPAMAFANFRRILRLSTFEKRKSREYEHVRRDLDPNEVWEIVGELGDGAFGKVYKAKNKETGALAAAKVIETKSEEE LEDYIVEIEILATCDHPYIVKLLGAYYHDGKLWIMIEFCPGGAVDAIMLELDRGLTEPQIQVVCRQMLEALNFLHSKRIIHRDLKAGNVL MTLEGDIRLADFGVSAKNLKTLQKRDSFIGTPYWMAPEVVMCETMKDTPYDYKADIWSLGITLIEMAQIEPPHHELNPMRVLLKIAKSDP PTLLTPSKWSVEFRDFLKIALDKNPETRPSAAQLLEHPFVSSITSNKALRELVAEAKAEVMEEIEDGRDEGEEEDAVDAASTLENHTQNS SEVSPPSLNADKPLEESPSTPLAPSQSQDSVNEPCSQPSGDRSLQTTSPPVVAPGNENGLAVPVPLRKSRPVSMDARIQVAQEKQVAEQG GDLSPAANRSQKASQSRPNSSALETLGGEKLANGSLEPPAQAAPGPSKRDSDCSSLCTSESMDYGTNLSTDLSLNKEMGSLSIKDPKLYK KTLKRTRKFVVDGVEVSITTSKIISEDEKKDEEMRFLRRQELRELRLLQKEEHRNQTQLSNKHELQLEQMHKRFEQEINAKKKFFDTELE NLERQQKQQVEKMEQDHAVRRREEARRIRLEQDRDYTRFQEQLKLMKKEEALVCHRKELSANTAAFAKSAAMLGNSEDHTALSRALSQLA EVEEKIDQLHQEQAFADFYMFSELLSDYIRLIAAVKGVFDHRMKCWQKWEDAQITLLKKREAEAKMMVANKPDKIQQAKNEIREWEAKVQ | 961_STK10_SNX2 |
Top |
Comparison of Fusion Protein Isoforms |
Superimpose the 3D Structures Among All Fusion Protein Isoforms * Download the pdb file and open it from the molstar online viewer. |
Comparison of the Secondary Structures of Fusion Protein Isoforms |
Top |
Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB |
Top |
pLDDT score distribution |
pLDDT score distribution of the predicted fusion protein structures from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. * The blue color at the bottom marks the best active site residues. |
257_STK10_SNX2.png |
257_STK10_SNX2.png |
Top |
Potential Active Site Information |
The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite. |
Kinase Fusion AA seq ID in KinaseFusionDB | Site score | Size | Dscore | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
Top |
Ramachandran Plot of Kinase Fusion Protein Structure |
Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide. |
257_STK10_SNX2_ramachandran.png |
Top |
Virtual Screening Results |
Distribution of the average docking score across all approved kinase inhibitors. Distribution of the number of occurrence across all approved kinase inhibitors. |
5'-kinase fusion protein case |
3'-kinase fusion protein case |
Top |
Drug information from DrugBank of the top 20 interacting small molecules. * The detailed information of individual kinase inhibitors are available in the download page. |
Fusion gene name info | Drug | Docking score | Glide g score | Glide energy |
257_STK10_SNX2-DOCK_HTVS_1-001 | Lapatinib | -6.9249600000000004 | -7.01376 | -39.9452 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Lapatinib | -6.75201 | -6.84081 | -38.6337 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Ponatinib | -6.58863 | -6.79523 | -40.9093 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Ponatinib | -6.58863 | -6.79523 | -40.9093 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Ponatinib | -6.58863 | -6.79523 | -40.9093 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Upadacitinib | -6.564960000000001 | -6.5659600000000005 | -29.4436 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Netarsudil | -6.45158 | -6.462680000000001 | -42.1469 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Netarsudil | -6.45158 | -6.462680000000001 | -42.1469 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Pacritinib | -6.26082 | -6.2659199999999995 | -44.4561 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Pexidartinib | -6.23682 | -6.45362 | -31.2789 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Pexidartinib | -6.23682 | -6.45362 | -31.2789 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Tepotinib | -6.19219 | -6.19329 | -53.7964 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Upadacitinib | -5.95908 | -5.9600800000000005 | -25.447 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Upadacitinib | -5.94602 | -5.947019999999999 | -27.5244 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Gilteritinib | -5.945069999999999 | -5.97147 | -51.0447 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Gilteritinib | -5.945069999999999 | -5.97147 | -51.0447 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Pralsetinib | -5.78596 | -5.87746 | -55.9459 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Ponatinib | -5.730919999999999 | -6.48562 | -44.9637 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Ponatinib | -5.730919999999999 | -6.48562 | -44.9637 |
257_STK10_SNX2-DOCK_HTVS_1-001 | Ponatinib | -5.730919999999999 | -6.48562 | -44.9637 |
Top |
Kinase-Substrate Information of STK10_SNX2 |
Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
STK10 | O94804 | human | RDX | P35241 | T564 | AGRDKyKtLRQIRQG | ERM_C |
STK10 | O94804 | human | EZR | P15311 | T567 | QGRDkyKtLRQIRQG | ERM_C |
STK10 | O94804 | human | PLK1 | P53350 | T210 | YDGERKktLCGtPNy | Pkinase |
STK10 | O94804 | human | MSN | P26038 | T558 | LGRDKyKtLRQIRQG | ERM_C |
Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
Enriched GO biological processes of the phosphorylation target genes of the kinase |
Kinase | GOID | GO term | P.adjust |
STK10 | ID | Description | 0.00e+00 |
STK10 | GO:1902946 | protein localization to early endosome | 1.25e-07 |
STK10 | GO:1905668 | positive regulation of protein localization to endosome | 1.25e-07 |
STK10 | GO:1905666 | regulation of protein localization to endosome | 1.25e-07 |
STK10 | GO:1903651 | positive regulation of cytoplasmic transport | 1.49e-07 |
STK10 | GO:2000641 | regulation of early endosome to late endosome transport | 2.54e-07 |
STK10 | GO:0036010 | protein localization to endosome | 6.39e-07 |
STK10 | GO:0045732 | positive regulation of protein catabolic process | 7.22e-07 |
STK10 | GO:1902115 | regulation of organelle assembly | 7.22e-07 |
STK10 | GO:1903649 | regulation of cytoplasmic transport | 7.22e-07 |
STK10 | GO:0045022 | early endosome to late endosome transport | 1.73e-06 |
STK10 | GO:0061028 | establishment of endothelial barrier | 2.01e-06 |
STK10 | GO:0098927 | vesicle-mediated transport between endosomal compartments | 2.01e-06 |
STK10 | GO:0042176 | regulation of protein catabolic process | 3.85e-06 |
STK10 | GO:0001885 | endothelial cell development | 3.89e-06 |
STK10 | GO:1903829 | positive regulation of protein localization | 9.79e-06 |
STK10 | GO:0045446 | endothelial cell differentiation | 2.53e-05 |
STK10 | GO:0008360 | regulation of cell shape | 3.43e-05 |
STK10 | GO:0003158 | endothelium development | 3.46e-05 |
STK10 | GO:0072697 | protein localization to cell cortex | 3.58e-05 |
STK10 | GO:0016482 | cytosolic transport | 6.43e-05 |
STK10 | GO:0032388 | positive regulation of intracellular transport | 8.26e-05 |
STK10 | GO:0002064 | epithelial cell development | 9.52e-05 |
STK10 | GO:0022604 | regulation of cell morphogenesis | 1.40e-04 |
STK10 | GO:0032386 | regulation of intracellular transport | 3.38e-04 |
STK10 | GO:0010737 | protein kinase A signaling | 3.47e-04 |
STK10 | GO:1990778 | protein localization to cell periphery | 3.61e-04 |
STK10 | GO:0032535 | regulation of cellular component size | 4.01e-04 |
STK10 | GO:0140694 | non-membrane-bounded organelle assembly | 5.18e-04 |
STK10 | GO:0022406 | membrane docking | 1.77e-03 |
STK10 | GO:1904375 | regulation of protein localization to cell periphery | 3.80e-03 |
STK10 | GO:0030010 | establishment of cell polarity | 4.77e-03 |
STK10 | GO:0051017 | actin filament bundle assembly | 4.92e-03 |
STK10 | GO:0061572 | actin filament bundle organization | 5.01e-03 |
STK10 | GO:0008361 | regulation of cell size | 6.24e-03 |
STK10 | GO:0007051 | spindle organization | 7.07e-03 |
STK10 | GO:0007163 | establishment or maintenance of cell polarity | 8.75e-03 |
STK10 | GO:0072659 | protein localization to plasma membrane | 1.37e-02 |
STK10 | GO:1901990 | regulation of mitotic cell cycle phase transition | 1.84e-02 |
STK10 | GO:0030953 | astral microtubule organization | 1.84e-02 |
STK10 | GO:0051081 | nuclear membrane disassembly | 1.84e-02 |
STK10 | GO:0051660 | establishment of centrosome localization | 1.84e-02 |
STK10 | GO:0071803 | positive regulation of podosome assembly | 1.84e-02 |
STK10 | GO:0010639 | negative regulation of organelle organization | 1.84e-02 |
STK10 | GO:0030397 | membrane disassembly | 1.94e-02 |
STK10 | GO:0034111 | negative regulation of homotypic cell-cell adhesion | 1.97e-02 |
STK10 | GO:0071394 | cellular response to testosterone stimulus | 1.97e-02 |
STK10 | GO:0032530 | regulation of microvillus organization | 1.97e-02 |
STK10 | GO:0032536 | regulation of cell projection size | 1.97e-02 |
STK10 | GO:0070486 | leukocyte aggregation | 1.97e-02 |
Top |
Related Drugs to STK10_SNX2 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Distribution of the number of studies mentioning STK10-SNX2 and kinase inhibitors the PubMed Abstract (04-01-2024) |
Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to STK10_SNX2 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
MeSH ID | MeSH term |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
Clinical Trials from clinicaltrials.gov (06-17-2024) |
Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |